Intellia Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Good morning. Thanks for joining us for another session at the 44th JP Morgan Healthcare conference. I'm Brian Cheng, one of the senior biotech analysts here at the firm. On stage, we have Intellia Therapeutics. I will now pass the mic to their CEO John Lander for a short presentation, followed by a live audience Q&A. John, the stage is yours.
Thank you, Brian. I appreciate the opportunity to give you a sense of where we are, intelia Therapeutics, as we begin the new year here.
This is our forward-looking statement. It's available on the website if people want to examine it further.
Okay. So, Intellia has been a leader in the CRISPR, medicine space, since it's outset, 2014. We've been, leaders in many respects, but have emphasized work in the in vivo treatment of genetic diseases. From our outset in 2014, here we stand, on the verge of completing trials that will lead to some of the first approved agents for
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
